11 September 2018
Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.
17 August 2018
A blood test can help detect whether patients with advanced prostate cancer will respond to a certain treatment, according to a new study. This approach could help better inform the choice of therapy and lead to improved outcomes. In the study, researchers used a liquid biopsy test developed by Epic Sciences to examine circulating tumor cells (CTCs) in blood samples from 142 patients with advanced prostate cancer deciding whether to switch from hormone-targeting therapy to chemotherapy.
03 August 2018
Celtaxsys’ oral anti-inflammatory drug for cystic fibrosis, acebilustat, cleared a phase 2 study by demonstrating meaningful improvements in pulmonary exacerbations, or the acute worsening of symptoms such as heavy coughing or shortness of breath, combined with sharp decreases in lung function following irreversible organ damage.
29 June 2018
NovaMedica, a Russian pharmaceutical manufacturer and portfolio company of RUSNANO, has registered Fissario®, a unique drug for the treatment of proctological disorders based on a new mechanism of action not used in the products currently available on the market. This is the first drug developed under NovaMedica’s own R&D program. According to the plans, it will become available to patients as early as in 2019.
03 May 2018
What is the way of development of the Russian pharma until 2030? What priorities in the development and challenges will be topical for the industry today and tomorrow? These are the questions which occupy minds of all key players of the market, experts and industry regulators. Sure thing! The stage where the Russian pharmaceutical industry is now, can definitely be called transitional – review of results of the state program Pharma-2020 and discussion of principals of the new state program Pharma 2030.
03 May 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region.
13 March 2018
NovaMedica, a Russian pharmaceutical company and investment project of Rusnano, concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga region. The SPIC provides for building from scratch a plant for sterile injectable dosage forms. As part of the project, NovaMedica will invest more than three billion rubles to establish the plant. So far, this is the largest SPIC in the Russian pharmaceutical industry in terms of investments.
12 February 2018
NovaMedica, a Russian pharmaceutical company and the investment project of RUSNANO, has announced the collaboration in the area of knowledge and technology transfer between NovaMedica Innotech, an R&D center, and Evonik, a German company and a leader in the global market of excipients for pharmaceutical industry.
02 February 2018
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.
22 January 2018
Since 2011, Russian policy has favoured local production in eorts to reduce reliance on pharmaceutical imports. Vladimir Putin’s ‘Pharma 2020’ policy pushes for as much 90% of drugs consumed in Russia to be made domestically by 2020. Such policies have led multinationals to tap the market through collaborations with domestic drugmakers. Pfizer, for example, teamed with Russian pharma firm NovaMedica last May to build an aseptic manufacturing plant in.
21 September 2018
21 September 2018
20 September 2018
20 September 2018